1
40
1
-
Text
A resource consisting primarily of words for reading. Examples include books, letters, dissertations, poems, newspapers, articles, archives of mailing lists. Note that facsimiles or images of texts are still of the genre Text.
URL Address
<a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">http://doi.org/10.1016/s0272-6386(99)70329-x</a>
Pages
E8–E8
Issue
2
Volume
33
Dublin Core
The Dublin Core metadata element set is common to all Omeka records, including items, files, and collections. For more information see, http://dublincore.org/documents/dces/.
Title
A name given to the resource
Chronic lymphocytic leukemia-associated membranous glomerulopathy: remission with fludarabine.
Publisher
An entity responsible for making the resource available
American journal of kidney diseases : the official journal of the National Kidney Foundation
Date
A point or period of time associated with an event in the lifecycle of the resource
1999
1999-02
Subject
The topic of the resource
Antineoplastic Agents/*therapeutic use; B-Cell/*complications; Biopsy; Chronic; Female; Glomerulonephritis; Humans; Kidney/pathology; Leukemia; Lymphocytic; Membranous/diagnosis/*drug therapy/etiology; Vidarabine/*analogs & derivatives/therapeutic use
Creator
An entity primarily responsible for making the resource
Butty H; Asfoura J; Cortese F; Doyle M; Rutecki G
Description
An account of the resource
In some individuals, chronic lymphocytic leukemia (CLL) may be associated with glomerular disease from membranous nephropathy with resultant nephrotic syndrome. CLL is characterized by abnormal immunoregulation with a malignant clonal proliferation of lymphocytes. The association between the abnormal clone and nephrotic syndrome is suggested in some cases by the remission of proteinuria with a reduction in abnormal lymphocyte number after treatment with antineoplastic agents. For the first time, we describe a patient with CLL and associated membranous glomerulopathy whose nephrotic syndrome remitted after treatment with fludarabine, a new purine analogue used in the treatment of refractory CLL.
Identifier
An unambiguous reference to the resource within a given context
<a href="http://doi.org/10.1016/s0272-6386(99)70329-x" target="_blank" rel="noreferrer noopener">10.1016/s0272-6386(99)70329-x</a>
Rights
Information about rights held in and over the resource
Article information provided for research and reference use only. All rights are retained by the journal listed under publisher and/or the creator(s).
1999
American journal of kidney diseases : the official journal of the National Kidney Foundation
Antineoplastic Agents/*therapeutic use
Asfoura J
B-Cell/*complications
Biopsy
Butty H
Chronic
Cortese F
Department of Internal Medicine
Doyle M
Female
Glomerulonephritis
Humans
Kidney/pathology
Leukemia
Lymphocytic
Membranous/diagnosis/*drug therapy/etiology
NEOMED College of Medicine
Rutecki G
Vidarabine/*analogs & derivatives/therapeutic use